Curated News
By: NewsRamp Editorial Staff
March 04, 2026
Voyageur's Natural Barium Hits 98.8% Purity, Advances to Human Trials
TLDR
- Voyageur Pharmaceuticals' natural barium sulfate achieves 98.8% purity, potentially offering a cost-effective, high-quality alternative to synthetic contrast media with a secure North American supply chain.
- Voyageur's barium sulfate API passed all USP tests with 98.1-99.4% purity, micronized to 1-10µm particles in cGMP conditions, advancing to stage two of Alberta Innovates' program.
- Developing domestic natural barium sulfate reduces reliance on imports, improving supply reliability and cost efficiency for hospitals, potentially enhancing patient access to medical imaging contrast agents.
- Voyageur sourced pharmaceutical-grade barium from its Frances Creek property, achieving rare natural purity above 98% that could replace synthetic products in medical imaging.
Impact - Why it Matters
This development matters because it represents a potential breakthrough in securing a domestic, high-quality supply chain for essential medical imaging contrast agents. Currently, most pharmaceutical barium sulfate is synthetically produced, often overseas, which can lead to supply chain vulnerabilities, higher costs, and variable quality. Voyageur's success in purifying natural barite to exceed pharmaceutical standards could reduce North American healthcare systems' dependence on foreign sources, improving cost efficiency and supply reliability for hospitals. For patients, this could translate into more accessible and potentially more effective imaging diagnostics. Furthermore, a successful vertically integrated model from mine to medicine sets a precedent for pharmaceutical sovereignty in critical medical supplies, an issue highlighted by global supply chain disruptions in recent years.
Summary
Voyageur Pharmaceuticals Ltd., a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, has achieved a significant milestone with independent laboratory test results confirming the exceptional purity of its barium sulfate active pharmaceutical ingredient (API). The testing, conducted by SGS Laboratories in Mississauga, Ontario, as part of the Alberta Innovates AICE-Market Access Program, revealed that the barium sulfate sourced from the company's Frances Creek property in British Columbia achieved an average purity of 98.8% BaSO4, exceeding the United States Pharmacopeia (USP) monograph requirement of 97.5%. The material also successfully passed all USP tests, including those for heavy metals and microbiological requirements, and was efficiently micronized to ultra-fine particle sizes suitable for medical use. CEO Brent Willis hailed these results as a major de-risking milestone, bringing the company closer to establishing a fully integrated, secure North American supply chain for barium contrast media.
The successful testing paves the way for Voyageur to advance to stage two of the Alberta Innovates program, which involves manufacturing barium contrast agents for an upcoming clinical trial designed by Chief Scientific Officer Dr. Iryna Saranchova. This trial, targeted for completion in the fourth quarter of 2026, will compare Voyageur's investigational agents against current standard-of-care options for gastrointestinal Computed Tomography and fluoroscopic imaging. Positive outcomes are expected to validate the clinical performance of Voyageur's products, strengthen regulatory positioning with Health Canada and the FDA, and accelerate market adoption. The company, which already holds Health Canada licenses for five barium contrast products, aims to disrupt the market by replacing synthetically produced barium sulfate with a higher-quality, lower-cost natural alternative from its domestic resource.
In addition to the technical progress, Voyageur announced several corporate developments, including the issuance of 378,651 Deferred Share Units (DSUs) to directors and a consultant, and the grant of 4,300,000 stock options to directors and officers. The company also proposed issuing units to a third-party provider for financial advisory services, subject to TSX Venture Exchange approval. These moves align with Voyageur's ambitious vision to become the first vertically integrated company in the radiology contrast media market, controlling costs from "the Earth to the Bottle." The original release can be viewed on www.newmediawire.com, highlighting the company's progress toward reducing reliance on imported materials and improving supply reliability for hospitals and patients across North America.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Voyageur's Natural Barium Hits 98.8% Purity, Advances to Human Trials
